A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera
Polycythemia vera (PV) is a hematopoietic stem cell disorder characterized by JAK2V617F, a mutation that gives rise to erythrocytosis. Our previous studies have shown that arachidonate 5-lipoxygenase (Alox5) is a critical driver in PV and the inhibition of the Alox5 pathway attenuates JAK2V617F-ind...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-06-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849472100353441792 |
|---|---|
| author | Yi Shan Ngoc DeSouza Noah Littman Qiang Qiu Kathy Nguyen Yehua Yu Golam Mohi Shaoguang Li |
| author_facet | Yi Shan Ngoc DeSouza Noah Littman Qiang Qiu Kathy Nguyen Yehua Yu Golam Mohi Shaoguang Li |
| author_sort | Yi Shan |
| collection | DOAJ |
| description |
Polycythemia vera (PV) is a hematopoietic stem cell disorder characterized by JAK2V617F, a mutation that gives rise to erythrocytosis. Our previous studies have shown that arachidonate 5-lipoxygenase (Alox5) is a critical driver in PV and the inhibition of the Alox5 pathway attenuates JAK2V617F-induced PV development in mice. However, the molecular mechanism underlying the function of Alox5 in PV remains elusive. It is well established that leukotrienes are important downstream molecules synthesized through the Alox5 pathway in leukocytes and play a key role in mediating Alox5 functions in human asthma. In this study, we found that Montelukast, a leukotriene receptor antagonist, inhibits cell proliferation and induces apoptosis in JAK2V617F-cell lines. Further in vivo studies demonstrated that Montelukast treatment suppresses the development of PV induced by JAK2V617F in mice, comparable to the effect of Alox5 inhibition on PV development. Notably, the inhibitory effect of Montelukast on PV is dependent on selectively eradicating PV stem cells while sparing their normal counterparts. Moreover, we found that Montelukast synergizes with the JAK2 inhibitor (ruxolitinib) to inhibit proliferation of JAK2V617F-expressing hematopoietic cells in vitro and in JAK2V617F mice. Finally, we showed that Montelukast induces caspase-3- and PARP-associated apoptosis of JAK2V617F-expressing cells. These findings indicate that Montelukast is a promising candidate agent and could be combined with an JAK2 inhibitor (such as ruxolitinib) for PV treatment.
|
| format | Article |
| id | doaj-art-55080bfe4a2b4940b319417fdac90ca7 |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-55080bfe4a2b4940b319417fdac90ca72025-08-20T03:24:37ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-06-01999110.3324/haematol.2024.287186A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia veraYi Shan0Ngoc DeSouza1Noah Littman2Qiang Qiu3Kathy Nguyen4Yehua Yu5Golam Mohi6Shaoguang Li7Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MassachusettsDepartment of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts Polycythemia vera (PV) is a hematopoietic stem cell disorder characterized by JAK2V617F, a mutation that gives rise to erythrocytosis. Our previous studies have shown that arachidonate 5-lipoxygenase (Alox5) is a critical driver in PV and the inhibition of the Alox5 pathway attenuates JAK2V617F-induced PV development in mice. However, the molecular mechanism underlying the function of Alox5 in PV remains elusive. It is well established that leukotrienes are important downstream molecules synthesized through the Alox5 pathway in leukocytes and play a key role in mediating Alox5 functions in human asthma. In this study, we found that Montelukast, a leukotriene receptor antagonist, inhibits cell proliferation and induces apoptosis in JAK2V617F-cell lines. Further in vivo studies demonstrated that Montelukast treatment suppresses the development of PV induced by JAK2V617F in mice, comparable to the effect of Alox5 inhibition on PV development. Notably, the inhibitory effect of Montelukast on PV is dependent on selectively eradicating PV stem cells while sparing their normal counterparts. Moreover, we found that Montelukast synergizes with the JAK2 inhibitor (ruxolitinib) to inhibit proliferation of JAK2V617F-expressing hematopoietic cells in vitro and in JAK2V617F mice. Finally, we showed that Montelukast induces caspase-3- and PARP-associated apoptosis of JAK2V617F-expressing cells. These findings indicate that Montelukast is a promising candidate agent and could be combined with an JAK2 inhibitor (such as ruxolitinib) for PV treatment. https://haematologica.org/article/view/12091 |
| spellingShingle | Yi Shan Ngoc DeSouza Noah Littman Qiang Qiu Kathy Nguyen Yehua Yu Golam Mohi Shaoguang Li A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera Haematologica |
| title | A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera |
| title_full | A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera |
| title_fullStr | A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera |
| title_full_unstemmed | A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera |
| title_short | A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2</i>V617F-induced polycythemia vera |
| title_sort | blockade of leukotriene mediated alox5 function provides a new strategy for the treatment of i jak2 i v617f induced polycythemia vera |
| url | https://haematologica.org/article/view/12091 |
| work_keys_str_mv | AT yishan ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT ngocdesouza ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT noahlittman ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT qiangqiu ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT kathynguyen ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT yehuayu ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT golammohi ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT shaoguangli ablockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT yishan blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT ngocdesouza blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT noahlittman blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT qiangqiu blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT kathynguyen blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT yehuayu blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT golammohi blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera AT shaoguangli blockadeofleukotrienemediatedalox5functionprovidesanewstrategyforthetreatmentofijak2iv617finducedpolycythemiavera |